AbbVie (ABBV.US) invests $1.4 billion to acquire the neuroscience technology company Aliada Therapeutics.
AbbVie has agreed to acquire all outstanding shares of Aliada Therapeutics, a biotechnology company focused on neuroscience, for 1.4 billion US dollars in cash.
Sector Update: Health Care Stocks Edge Up Monday Afternoon
Sector Update: Health Care
Top Midday Stories: Boeing Launches Public Offerings; McDonald's Quarter Pounder to Return to Menus This Week
AbbVie Is Buying an Alzheimer's Drug for More Than $1 Billion
Sweetgreen, Tesla, Digital Realty Trust And A Health Care Stock On CNBC's 'Final Trades'
AbbVie to Buy Aliada Therapeutics for $1.4B in Cash
Express News | Abbvie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
Press Release: AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
Apple, Microsoft, Exxon, and More Stocks to Watch
About 75% of Companies That Reported Earnings This Week Delivered EPS Wins-Earnings Scorecard
Preview -- Barron's
Forecasting The Future: 11 Analyst Projections For AbbVie
AbbVie Is Maintained at Buy by Citigroup
AbbVie Analyst Ratings
If You Invested $10,000 In AbbVie Stock 10 Years Ago, How Much Would You Have Now?
AbbVie Inc.'s (NYSE:ABBV) Price In Tune With Earnings
Curious About AbbVie (ABBV) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Express News | Abbvie : Citigroup Raises Target Price to $215 From $170
Earnings Preview: AbbVie to Report Financial Results Pre-market on October 30
$AbbVie(ABBV.US)$ is scheduled to release its financial results pre-market on October 30 ET. Earnings PreviewAnalysts estimate $AbbVie(ABBV.US)$ to post revenue of USD14.28B for 2024Q3, up 2.53% YOY;